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Amyloid hypothesis of Alzheimer’s disease (AD) has recently been challenged by the
increasing evidence for the role of vascular and hemostatic components that impair oxygen
delivery to the brain. One such component is fibrin clots, which, when they become resis-
tant to thrombolysis, can cause chronic inflammation. It is not known, however, why some
cerebral thrombi are resistant to the fibrinolytic degradation, whereas fibrin clots formed at
the site of vessel wall injuries are completely, although gradually, removed to ensure proper
wound healing. This phenomenon can now be explained in terms of the iron-induced free
radicals that generate fibrin-like polymers remarkably resistant to the proteolytic degra-
dation. It should be noted that similar insoluble deposits are present in AD brains in the
form of aggregates with Abeta peptides that are resistant to fibrinolytic degradation. In
addition, iron-induced fibrin fibers can irreversibly trap red blood cells (RBCs) and in this
way obstruct oxygen delivery to the brain and induce chronic hypoxia that may contribute
to AD. The RBC-fibrin aggregates can be disaggregated by magnesium ions and can also
be prevented by certain polyphenols that are known to have beneficial effects in AD. In
conclusion, we argue that AD can be prevented by: (1) limiting the dietary supply of trivalent
iron contained in red and processed meat; (2) increasing the intake of chlorophyll-derived
magnesium; and (3) consumption of foods rich in polyphenolic substances and certain
aliphatic and aromatic unsaturated compounds. These dietary components are present in
the Mediterranean diet known to be associated with the lower incidence of AD and other
degenerative diseases.
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INTRODUCTION
In this article we present a concept according to which the biolog-
ically most damaging hydroxyl radicals generated by free iron, and
prevented by magnesium (Mg) ions, may cause neurodegenera-
tive diseases. The primary target of the iron-induced free radicals
is blood fibrinogen that becomes converted to fibrin-like material,
which interferes with the effective delivery of oxygen by the altered
red blood cells (RBCs) and consequently damages the brain’s neu-
rological functions. We also review data on the protective role Mg,
particularly in its ionized form. Mg has been shown to inhibit
in vivo thrombosis (Ravn et al., 1997; Mussoni et al., 2001; Barba-
gallo et al., 2011). In this paper, the mechanism of its action will
be discussed.
Efficient delivery of oxygen to tissues and organs is paramount
for normal functioning of living organisms. It is well known
that the brain is particularly susceptible to even short periods of
hypoxia, and the chronic shortage of oxygen can cause irreversible
neurologic consequences (Peers et al., 2007; Grammas et al., 2011).
On the other hand it is generally believed that the prolonged
ischemia followed by rapid reperfusion causes so-called “oxidative
stress”believed to be preventable by the use of antioxidants (Nuno-
mura et al., 2001). Yet potent antioxidants such as vitamin C and E
have failed to provide health benefits in the degenerative diseases
that are supposedly due to excessive blood oxygenation (Steinhubl,
2008). At the same time numerous natural substances endowed
with oxidative properties (e.g., certain polyphenols) have been
shown to provide protection against the damage caused by oxygen-
centered free radicals (Summers, 2004; Lipinski, 2011). Therefore,
in the current paper we present evidence for the neuroprotective
effects of certain dietary components, such as Mg, polyphenols,
aliphatic, and/or aromatic unsaturated natural substances.
VASCULAR AND HEMOSTATIC FACTORS
The prevailing amyloid hypothesis in Alzheimer’s disease (AD)
has recently been challenged by several authors (Pimplikar, 2009;
Skaper, 2012; Chetelat, 2013). This challenge is supported by the
increasing evidence for the role of vascular components (Kovacic
and Fuster, 2012; Diomedi and Misaggi, 2013; Sery et al., 2013),
as well as hemostatic factors in neurological diseases and particu-
larly in AD (Kalaria, 2003; Gupta et al., 2005; Kling et al., 2013).
Thus, isoforms of fibrinogen gamma chain were identified among
insoluble proteins in AD brains (Choi et al., 2002), and it was also
shown that fibrin interacted with beta-amyloid protein (Merkle
et al., 1996). Other researchers have demonstrated the perivascu-
lar leakage of fibrinogen around brain microvessels in AD and
HIV-related neurological disorders (Fiala et al., 2002), as well as
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the presence of fibrin in CNS (Inoue et al., 1997). The existence
of a protease-resistant complex of fibrinogen and albumin was
also found in AD brains (Lipinski and Sajdel-Sulkowska, 2006).
Moreover, Paul et al. (2007) documented that fibrin accelerates
neurovascular damage in AD. In acute cerebral lesions of multiple
sclerosis tissue plasminogen activator (tPA) was co-localized with
fibrin(ogen) on large diameter axons, which finding was inter-
preted as an attempt to remove fibrin deposits and restore normal
axon function (Gveric et al., 2001). Brain injury accompanied
by cerebrovascular fibrin deposition was revealed in a hyperten-
sive stroke model (Ninomia et al., 2000). Fibrin clearance and/or
deposition was suggested to be a key regulatory mechanism for
Schwann differentiation and nerve cell damage (Davalos et al.,
2012) due to the altered fibrin structure. It is furthermore known
that amyloid-beta delays fibrin clot lyses by altering fibrin structure
and attenuating plasminogen binding to fibrin (Zamolodchikov
and Strickland, 2012). Recently, Hultman et al. (2013) confirmed
that fibrin(ogen) is deposited in the AD neurovasculature and
interacts with beta-amyloid, resulting in increased formation of
blood clots. Also, in postmortem investigations,an increased depo-
sition of fibrin(ogen) was observed in AD cases compared with
non-demented controls, and the authors suggested that a strong
correlation exists between cerebral amyloid angiopathy severity
and fibrin(ogen) deposition. There is therefore extensive evidence
of the role of oxidative damage in the brain of patients with
AD although the exact process is not fully understood. How-
ever, oxidative stress could be linked to alterations of amyloid-beta
metabolism and beneficial effects of antioxidants against amyloid-
beta toxicity or AD may be of great importance and are shown in
many studies (Chakrabarti et al., 2013).
It is also of interest to note that high blood fibrinogen is associ-
ated with an increased risk of AD (van Oijen et al., 2005), and that
antibodies to beta-amyloid peptide react with individual chains
of fibrinogen (Stern et al., 1990). Moreover, amyloid fibrils were
shown to contain fibrinogen antigen-reactive material (Ahn et al.,
2010; Cortes-Canteli et al., 2010). It is of interest to note that AD is
closely associated with atherosclerosis (Kovacic and Fuster, 2012;
Yarchoan et al., 2012) in which blood fibrinogen levels are typi-
cally increased (Lipinska et al., 1976; van Oijen et al., 2005). Yet
some people may develop a “pure” form of AD based strictly on
the pathologic consequences of insoluble amyloid-beta without
manifestation of the vascular disease as emphasized by Schneider
et al. (2007).
Yet, despite intensive research, we still do not understand how
fibrin is being formed in cerebral microcirculation, especially
following episodes of hypoxia/ischemia. In contrast to coronary
circulation, very few blood components are present in the extravas-
cular brain space, as a result of a selective permeability of blood-
brain-barrier (BBB). Perhaps it is not surprising that one of such
components is tPA, which might serve as the first line of defense
against fibrin formed from plasma leaked after damage to BBB
(Gveric et al., 2001). On the other hand, it has been suggested that
this activator in conjunction with plasmin may aid the clearance of
Abeta peptide as shown in the brains of patients with AD (Melcher,
2004). Alternatively, plasmin formed in the cerebral extravascular
space can be neurotoxic, by activating metaloproteinases that are
known to degrade basement membrane matrix (Kaur et al., 2004).
IRON AND FREE RADICALS
Several investigators discuss the involvement of two transition
metals, iron and copper, in the pathogenesis of atherosclerosis
and AD (Brewer, 2007; Barnham and Bush, 2008; Silvestri and
Camaschella, 2008; Smith et al., 2010; Weinberg, 2010; Squitti,
2012; Zheng and Monnot, 2012). Out of these two redox met-
als, iron was shown to be particularly active in a number of
degenerative diseases (Kiechl et al., 1997; Brewer, 2007; Ahluwalia
et al., 2010; Depalma et al., 2010; Hahalis et al., 2011; Merono
et al., 2011) including neurological disorders (Beard and Connor,
2003; Ke and Ming Qian, 2003; Thomas and Jankovic, 2004; Kell,
2010). It should be emphasized that free iron can participate in
the formation reactive oxygen species (ROS) that, in turn, ini-
tiates so-called oxidative stress leading to AD (Casadesus et al.,
2004; Castellani et al., 2012), as well as to those associated with
aging (Szweda et al., 2002). The concept of labile iron pool was
recently developed, which may explain the connection between
iron and free-radical generation (Kruszewski, 2003; Breuer et al.,
2008; Benarroch, 2009). However, despite the fact that the concept
of oxidative stress has been generally accepted, there is no proof
of the involvement of oxidation processes in degenerative diseases
(Lipinski, 2011). On the other hand, the presence of biomolecules
enriched in one or more atoms of oxygen indicates the involve-
ment of a specific type of ROS – the hydroxyl radical. Hydroxyl
radicals are the most biologically damaging species, particularly
with respect to macromolecules such as proteins, nucleic acids,
and carbohydrates (Cheeseman et al., 1988; Lipinski, 2011). We
have recently documented that trivalent iron ion (Fe3+) reacts
with the hydroxyl group of water to produce a powerful hydroxyl
radical according to the following reaction:
Fe3+ + −OH+ → Fe2+ + ·OH
This reaction can be considered as a special case of the Fenton
reaction in which hydroxyl radicals are generated from divalent
iron ion in the presence of hydrogen peroxide. The need for the
oxidizing agent in the Fenton reaction led to a misleading concept
that hydroxyl radicals are formed as a, result of the oxidation reac-
tion. Whatever their origin, it should be emphasized that the most
important neurological consequence of the action of hydroxyl rad-
icals is their ability to convert soluble fibrinogen into an insoluble
fibrin-like polymer (Lipinski and Pretorius, 2012). A characteristic
feature of such a polymer is its resistance to the action of prote-
olytic enzymes that normally degrade fibrin(ogen) into smaller
polypeptide fragments.
The damaging effect of hydroxyl radicals can be explained
in terms of the following mechanism: the undesirable molecu-
lar interactions in blood proteins are prevented by holding their
hydrophobic groups inside the interior of protein tridimensional
structures stabilized by intra-molecular disulfide bonds. Once
these bonds are broken, the polypeptide chains become unfolded
with the consequent exposure of the hydrophobic domains, which
form inter-molecular bonds and result in the formation of large
a proteolytic enzymes, as is the case with human prion proteins
(Das et al., 2010) and bacterial hydrophobins (Kwan et al., 2006).
Moreover, in 2001, researchers suggested that free-radical-induced
protein aggregates resistant to proteases are responsible for the
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amyloid formation (Squier, 2001). It is worth noting that one of
the risk factors for AD is diabetes mellitus, in which excessive
generation of free radicals was may play a major pathogenic role
(Lipinski, 2001). This has recently resulted in raising intriguing
questions regarding the common denominator in AD and diabetes
(Craft, 2012; Adeghate et al., 2013; Vignini et al., 2013).
Another factor has been suggested to be involved in the patho-
genesis of AD, which is copper known to generate hydroxyl radicals
in hypoxia. This transition metal as well as iron are present in
normal brain tissue at normal concentrations, but are signifi-
cantly increased in cerebrospinal fluid of AD patients (Multhaup,
1995) and in AD brains (Markesbery and Carney, 1999; Altamura
and Muckenthaler, 2009). Moreover, transition metals have been
implicated in the generation of free-radical and in the aggregation
of amyloid protein in the brains of Alzheimer’s patients (Adlard
and Bush, 2006). The role of iron in neurotoxicity was recently
reviewed (Stankiewicz and Brass, 2009) and the iron overload in
the early stages of life was suggested to induce cognitive impair-
ment and the damage of the brain (de Lima et al., 2005). It is
possible that under the reducing conditions of hypoxia, these
metal ions generate hydroxyl radical with all its pathological con-
sequences (Dajas-Bailador et al., 1998; Ciriolo et al., 2000). An
imbalance between free-radical generation and scavenging was
suggested to be one of the earliest pathological events in AD
(Moreira et al., 2005).
Additional evidence for the involvement of hydroxyl radicals
in the pathogenesis of neurodegenerative diseases comes from the
experimental investigations showing the protective effect of a free-
radical scavenger ferulic acid in mouse neuroblastoma 2a cells (Yan
et al., 2012). Moreover, evidence for the involvement of free radi-
cals in these diseases comes from experimental studies with the use
of edaravone, a potent scavenger of hydroxyl radicals (Abe et al.,
2004). On the basis of its scavenging properties, this compound
was approved in Japan for the treatment of acute cerebral infarcts
within 24 h of onset (Watanabe et al., 1996). Diabetic neuropa-
thy was also shown to be prevented by edaravone in an animal
experimental study (Saini et al., 2007). Perhaps, the best evidence
for the connection between hypoxia and hydroxyl radical produc-
tion was provided by showing the protective effect of edaravone
in fetal lamb brain after umbilical cord occlusion (Nakajima et al.,
2006).
HEMORHEOLOGIC DISTURBANCES
Although the hydroxyl radical is considered by mainstream scien-
tists as an oxidant, it behaves as a reducing agent with respect to
disulfide bridges in plasma proteins leading to the unfolding and
scrambled refolding of the polypeptide chains. In this respect this
type of free radicals is similar to a dithiol-reducing agent that when
added to human whole blood causes rapid aggregation of RBC and
an irreversible polymerization of the plasma proteins (Egyud and
Lipinski, 1991). Thus, this in vitro phenomenon illustrates the
pathologic consequences of the exposure of hydrophobic forces
that are potentiated by antioxidants and prevented by the oxidiz-
ing agents (Pretorius et al., 2013a). For such a reason this concept
offers an explanation for the failure of antioxidant therapies in
the degenerative diseases – including the neurological disorders
(Steinhubl, 2008).
At the same time numerous natural products that are not
antioxidants were shown to provide protection against car-
diovascular and neurological diseases. Particularly, a group of
amphiphilic substances, known as “polyphenols” including resver-
atrol, epigallo-catechin-3-gallate (EGCG), certain anthocyanins,
and flavonols has been shown to be effective scavengers of hydroxyl
radicals (Lipinski, 2011). In addition, both EGCG and resvera-
trol were shown to cross BBB, a phenomenon that is not shared
by other polyphenols (Mandel et al., 2006; Srividhya et al., 2008;
Bieschke et al., 2010). However, most important biological func-
tion of polyphenols, is scavenging of hydroxyl radicals by means
of aromatic hydroxylation. This reaction may explain the abil-
ity of EGCG to disrupt RBC-parafibrin aggregates, as previously
reported by us (Pretorius et al., 2013b).
Continuous and unobstructed delivery of oxygen to the brain
by the RBCs depends on their membrane fluidity and the state
of aggregation that impairs the release of oxygen (Tateishi et al.,
2001). Despite decades of intensive research it is not known what
exactly causes RBC aggregation and disaggregation. Over 100 years
ago Polish physician, Edmund Biernacki, documented that the
phenomenon of erythrocyte sedimentation depends on the inter-
action with fibrinogen (Biernacki, 1897), the level of which in
plasma is frequently elevated in degenerative and inflammatory
diseases. Years later an argument was presented that it is not just
fibrinogen itself but thrombin-induced soluble fibrin monomers
that form bridges between individual cells and in this way increase
their sedimentation and/or aggregation (Lipinski et al., 1969). The
reason for this is that fibrin monomers are more hydrophobic
than fibrinogen itself (van Oss, 1990) and thus can more readily
interact with hydrophobic patches on RBC membranes. Thus, the
dramatic increase of hydrophobicity of soluble parafibrin fibrils
generated by hydroxyl radicals from fibrinogen makes them even
more potent inducers of RBC aggregation. Whatever the mech-
anism, it is obvious that fibrinogen plays a critical role in this
phenomenon, so the reduction of its reactivity seems to be of
great potential in AD and in other neurodegenerative disorders.
Davalos et al. (2012) have even suggested eliminating the effect of
fibrinogen by the therapeutic defibrination, which is not a very
realistic clinical practice.
Increased RBC sedimentation and/or their aggregation have
been observed in the degenerative diseases such as atherosclero-
sis and inflammation, which are known to be associated with AD
(Robinson et al., 1995; Andresdottir et al., 2003). Most recently
it was shown that thrombosis mediated by RBC is potentiated
by ferric chloride (Barr et al., 2013), which confirms our orig-
inal observation on the role of iron in pathologic blood coag-
ulation (Lipinski and Pretorius, 2012; Pretorius et al., 2013a,b).
Other researchers have also emphasized the role of hemorheol-
ogy in thrombosis and vascular diseases (Erikssen et al., 2000;
Natali et al., 2003; Baskurt et al., 2004; Nagy et al., 2010). It is
believed that the abnormalities in RBC obstruct oxygen delivery
to the brain (Tateishi et al., 2001; Mohanty et al., 2008; Tripathy
et al., 2013), which, in turn, causes hypoxia leading to chronic
inflammation (Eltzschig and Carmeliet, 2011; Wyss-Coray and
Rogers, 2012). Last but not least is the role of blood hemoly-
sis that releases trivalent iron (Woollard et al., 2009) with all
its pathologic consequences (Pretorius and Lipinski, 2013). It
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should be kept in mind that AD, especially when presented during
the later stages of life, presents as a co-occurrence with vascu-
lar pathology, such as white matter disease. The question that
now arises is exactly how damage due to hydroxyl radicals and
typical vascular pathology that may develop independently, are
interlinked. We suggest that the additional burden of the presence
of hydroxyl radical damage might cause a faster progression of the
disease.
INFLAMMATION
A large body of data indicates that inflammation is a hallmark of
AD and other neurodegenerative diseases (Tuppo and Arias, 2005;
Paul et al., 2007; Ray and Lahiri, 2009; Davalos et al., 2012; Wyss-
Coray and Rogers, 2012; Krstic and Knuesel, 2013). In view of a
close relationship between inflammation and hypoxia (Eltzschig
and Carmeliet, 2011) it is possible that the culprit is a persistent
obstruction of cerebral blood flow caused by the chronic forma-
tion of iron-induced fibrin/RBC aggregate. In another scenario
pathologic fibrin, being resistant to the proteolytic degradation,
may present itself to the innate immune system as a foreign body.
According to Mechnikov, inflammation is a protective adapta-
tion response to a foreign body that activates macrophages in
an attempt to eliminate it from a living organism (Palmblad,
2010). Whereas in most cases the powerful enzymatic machinery
of macrophages eventually digests foreign pathogens, the specific
hydrophobic properties of iron-induced material make it refrac-
tory to the proteolytic degradation, thus initiating a chronic state
of inflammation.
THE PROTECTIVE ROLE OF MAGNESIUM
Mg is a cofactor in numerous enzymes and plays a critical role
in many physiologic reactions, including the regulation of cell
membrane stability (Woolf, 1961; Elin, 1994; Fawcett et al., 1999).
Since Mg is not routinely measured in medical practice, its defi-
ciency may remain undetected for a long period of time (Touyz,
2004; Assadi, 2010). Large epidemiological studies indicate that
the inadequate dietary Mg intake and its low serum concentra-
tion are associated with insulin resistance, type 2 diabetes mellitus
(Corica et al., 2006; Huang et al., 2012) and with cardiovascu-
lar diseases (Amighi et al., 2004; Adamopoulos et al., 2009). In
addition, hypomagnesemia occurs frequently in association with
hypertension (Houston, 2011) and is related to all-cause mortality
(Reffelmann et al., 2011). It has also been argued that correcting
hypomagnesia may enhance memory (Slutsky et al., 2010) and
even prolong life (Rowe, 2012).
Mg deficiency is frequently encountered in critically ill patients
(Limaye et al., 2011), particularly those with systemic inflamma-
tion (Mazur et al., 2007; Weglicki, 2012). Although Mg deficiency
has been known for a long time to be correlated with throm-
botic diseases, the mechanism of its hemostatic function is not
well understood (Barbagallo et al., 2011). Total plasma Mg con-
centrations are remarkably constant in healthy subjects and do
not substantially change with aging (Romani, 2013) but its ion-
ized form, representing 55% of total Mg, has been shown to be
decreased in cardiovascular disease (Kupetsky-Rincon and Uitto,
2012) and in AD as well (Durlach, 1990; Cilliler et al., 2007;
Barbagallo et al., 2011).
Health beneficial effects of Mg can be explained by the results
of our finding of its anticoagulant properties, as shown in Table 1.
As shown in Table 1, Mg progressively prolonged coagulation
times until the samples became uncoagulable at 8 mM concentra-
tion. It is important to note that this novel effect can be observed
only with native whole blood and is absent when tested with
plasma clotted with thrombin. It has to be concluded, therefore,
that the Mg ions interfere with the intrinsic activation of pro-
thrombin. This is a very important fact that explains why even
large doses of Mg administered to humans have never caused
bleeding from the site of vascular injury, at which tissue factor-
activated thrombin fulfilled its hemostatic function (Huntsman
et al., 1960; Ravn et al., 1997; Ames et al., 1999; Mussoni et al.,
2001). The dramatic influence of Mg on blood coagulation may
explain its beneficial effects in numerous diseases described by
several investigators (Ceremuzynski et al., 2000; Muir et al., 2004;
Shechter,2010; Barbagallo et al., 2011; Kupetsky-Rincon and Uitto,
2012; Muroi et al., 2012; Albrecht et al., 2013). An important fact
described by us has to be emphasized – Mg anti-coagulated blood
is hemostatically effective as a result of its preserved ability to
form functional clots with thrombin that is physiologically gener-
ated by tissue factor at the site of vessel wall injury. Apparently, by
contrast to coumarin-derived anticoagulants, Mg does not affect
prothrombin biosynthesis, but inhibits its conversion to thrombin
(Table 1). The role of Mg in hemostasis and in hemorheology is
illustrated in Figure 1.
In the normal process of blood coagulation prothrombin is acti-
vated to enzyme thrombin that, in turn, converts plasma fibrino-
gen into soluble fibrin monomer(s). Subsequently, these species
undergo spontaneous linear polymerization, which leads to the
formation of fibrin fibrils that mechanically trap RBCs (left panel).
This phenomenon is very important for effective hemostasis and
subsequent fibrinolysis, which is prerequisite for normal wound
healing and the return of RBC into the circulation. By contrast
Table 1 | Effect of magnesium chloride on spontaneous coagulation of
whole blood and on thrombin-clotting times of plasma.
Final magnesium chloride concentration (mM)
0 2 4 6 8
Coagulation time (s) 250±32 485±47 670±50 1,220±84 >2,000
Clotting time (s) 26±3.5 27±3.5 25±3.6 24±2.7 23±2.4
To avoid interference of anticoagulants with magnesium the experiments were
done with freshly drawn whole blood and dialyzed plasma. Blood was drawn from
five healthy subjects (three males and two females, age 47–78) into plain evacu-
ated plastic tubes and immediately placed on ice. Subsequently 0.3 ml portions
of whole blood were pipetted into glass test-tubes (10 mm×70 mm) contain-
ing various concentrations of magnesium chloride (Sigma-Aldrich). Afterward the
test-tubes were incubated at 37°C and the coagulation times of blood recorded.
In a separate experiment human citrated plasma (pooled) was dialyzed against
phosphate buffered saline (PBS), pH 7.4, and 0.2 ml portions mixed with 20µL of
magnesium chloride solutions at various millimolar concentrations. Next, 20µL
of thrombin (100 U/ml; Sigma-Aldrich) was added to each tube and clotting time
recorded. Each experiment was done in triplicate and mean value±SD calculated.
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FIGURE 1 | Schematic representation of events leading to the formation of normal blood clot (left panel) and pathological iron-induced parafibrin
(right panel). Ca, calcium; Mg, magnesium; RBC, red blood cell.
to this physiological process, the pathological iron-induced blood
coagulation involves polymerization and irreversible entrapment
of RBCs (right panel). In this process hydrophobic soluble parafib-
rin interacts with the hydrophobic epitopes on RBC membranes,
forming large aggregates that are resistant to the fibrinolytic degra-
dation, and in this way prevents RBCs from effectively delivering
oxygen to the brain.
Magnesium plays a dual role in hemostasis: first it delays and/or
inhibits intravascular generation of fibrin monomers that might
have been formed as the results of prothrombin activation; second,
Mg ions prevent the interaction of soluble iron-induced parafib-
rin with RBC. Moreover, and even more importantly, preliminary
studies have shown that Mg ions disrupt RBC-parafibrin aggregate
as shown in Figure 2 and, in this way, allow erythrocytes to return
to the circulation (in whole blood smears of six AD patients and
noted in 100 RBCs per individual with and without added Mg).
Figure 2 shows representative images for the six patients.
It should be emphasized that a substantial difference exists
in the susceptibility to thrombolysis of these two types of clots.
In normal blood the intravascular thrombi can be effectively,
although only within a specific time window, eliminated with
the administration of fibrinolytic therapy. By contrast, abnormal
fibrin clots are remarkably resistant to the thrombolytic degrada-
tion, remain in the circulation and cause chronic inflammation.
This pathologic reaction can be prevented by the chelation of free
iron, scavenging of hydroxyl radicals, and/or administration of
ionized Mg. Of note, Mg sulfate therapy was shown to be effec-
tive in women with eclampsia and pre-eclampsia (Duley et al.,
2010; McDonald et al., 2012; Okereke et al., 2012). In addition,
low dietary Mg intake was demonstrated to be associated with the
risk of stroke (Larsson et al., 2012). Larger doses protect against
neurological deficit after brain injury (McIntosh et al., 1989) and
were shown to improve insulin sensitivity in non-diabetic sub-
jects (Guerrero-Romero et al., 2004) and in type 2 DM patients
(Rodriguez-Moran and Guerrero-Romero, 2003; Kim et al., 2010).
OTHER NEUROPROTECTIVE FACTORS
It is well known that a healthy diet, rich in polyunsaturated fatty
acids (PUFA) and polyphenols may have a positive effect on gen-
eral health. In particular, the Mediterranean diet has long been
known to have a positive effect on the health status of individuals,
including that of AD patients (Scarmeas et al., 2006; Thaipisuttikul
and Galvin, 2012). Countless papers show that the major compo-
nents of this diet include mono- and PUFA (in the form of fish oil),
minerals such as Mg, polyphenolic substances (red wine) and iron
chelating agents contained in citrus fruits (Feart et al., 2010; Gu
et al., 2010; Ayissi et al., 2013; Hu et al., 2013). All these substances
and agents are known to scavenge hydroxyl radical by virtue of aro-
matic hydroxylation, as well as to chelate iron (Thaipisuttikul and
Galvin, 2012). This specific combination of food products present
in the Mediterranean diet results in the inhibition of the generation
of parafibrin, which we suggest, contributes to the development
and progression of AD. It should also be noted that these beneficial
dietary effects may be important in prevention of cardiovascular
disease (Lipinski and Pretorius, 2013).
POLYUNSATURATED FATTY ACIDS
The brain is known to contain elevated quantities of PUFA that
paradoxically do not become oxidized by the high oxygen level
present in the brain. By contrast, PUFAs have been shown to be
neuroprotective, which can be explained in terms of their double
bonds acting as scavengers of hydroxyl radicals by converting them
to corresponding hydroxy-fatty acids (Czapski, 1984; Yavin et al.,
2002; Song et al., 2004). A highly unsaturated eicosapentanoic acid
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FIGURE 2 | SEM micrographs of red blood cells from Alzheimer’s disease (A) RBC smear; (B) with 3 mM MgCl2; (C) with 30 mM MgCl2. Scale=1µm.
was also shown to offer neuroprotection in the hippocampus of
gamma-irradiated rats (Lonergan et al., 2002) and in other exper-
imental models (Marszalek and Lodish, 2005). Concentrations of
essential fatty acids in plasma and RBCs and brain tissue were
found to be lower in patients with AD (Tully et al., 2003; Issa
et al., 2006; Milte et al., 2009) and in the aging brain (Lukiw and
Bazan, 2008). It is therefore not surprising that supplementation
with fish oil in AD patients substantially improved their mem-
ory (Corrigan et al., 1991; Yehuda et al., 1996; Sinn et al., 2010).
Moreover, consumption of fish was shown to be associated with a
reduced risk of AD (Morris et al., 2003), which might explain the
positive effect of the Mediterranean diet on cognitive functions
and dementia (Vassallo and Scerri, 2013; Kesse-Guyot et al., 2013;
King, 2013; Lourida et al., 2013). There are also other important
nutrients in this type of diet, such as minerals (e.g., Mg in the form
of chlorophyll contained in green vegetables) (Feart et al., 2012)
and polyphenolic substances that can protect the brain against the
pathogenic effect of iron overload.
POLYPHENOLS
Phenolic compounds and/or polyphenols constitute an important
group of compounds occurring in plants, comprising at least 8,000
different known structures – including simple phenols, phenolic
acids, coumarins and isocoumarins, naphthoquinones, xanthones,
stilbenes, flavonoids, and lignins (Rossi et al., 2008; Dudonne et al.,
2009). These natural substances exhibit a wide range of biological
effects including antibacterial-, anti-inflammatory-, antiallergic-,
antifungal-, antithrombotic-, and vasodilatory actions (Lin, 2011;
Angeloni et al., 2012; Kumar et al., 2012). More importantly the
substances are endowed with a capacity to scavenge hydroxyl
radicals (Zielonka et al., 2003; Lipinski, 2011), which might explain
their neuroprotective properties (Bieschke et al., 2010; Wang et al.,
2012).
Only very few polyphenols can cross BBB, the most active
in this respect being EGCG (Mandel et al., 2006; Meng et al.,
2010; Palhano et al., 2013; Srividhya and Kalaiselvi, 2013). Other
polyphenolic substances, such as curcumin (Baum and Ng, 2004;
Ringman et al., 2005; Zhao et al., 2012) have to be first metabo-
lized to small molecular-weight benzoic acid derivatives that are
easily absorbable and can enter the brain circulation after cross-
ing BBB (Kahle et al., 2007; Wang et al., 2012). These metabolites
are known to scavenge hydroxyl radical (·OH) by virtue of their
addition to double bonds with the formation of a corresponding
hydroxyl derivative:
R − CH = CH− R + ·OH → R − CH− (OH)− CH2− R.
It should be emphasized, however, that in the case of polyphe-
nols, only those with available ortho-position in their phenolic
rings will effectively scavenge hydroxyl radicals. A classic example
of such a mechanism, is the aromatic hydroxylation of salicylates
this constitutes a principle for the quantitative determination of
hydroxyl radicals in vivo (Grootveld and Halliwell, 1986; Ueno
et al., 2006). Anti-inflammatory effects of aspirin and salicylates
(Berk et al., 2013), as well as other small molecular-weight pheno-
lic substances including melatonin (Srinivasan et al., 2005; Galano,
2011), ferulic, chlorogenic, and coumaric acids (Srinivasan et al.,
2007), are very likely due to their ability to scavenge hydroxyl
radicals by means of aromatic hydroxylation.
CONCLUSION
In the present paper we argue that the neurological disturbances
in AD can be explained in terms of the hemostatic and hemorhe-
ologic effects of free iron in the cerebral circulation. It is known
that the iron pool increases with age because no mechanism exists
for its elimination from the human body. At a certain critical
Frontiers in Human Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 735 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lipinski and Pretorius Iron-induced fibrin in Alzheimer’s disease
concentration trivalent iron ions will react with water to give rise
to the biologically most reactive hydroxyl radicals that, in turn,
unfold and randomly refold fibrinogen polypeptide chains, which
results in the formation of a fibrin-like polymer (parafibrin). Such
a polymer, by contrast to a thrombin-induced fibril, is remark-
ably resistant to degradation by the fibrinolytic enzyme system.
In addition, soluble parafibrin interacts with hydrophobic patches
on RBC membranes, forming huge aggregates that obstruct cere-
bral blood flow and thus impair oxygen delivery to the brain.
In addition, parafibrin deposits residing for longer times in the
brain tissue may assume the role of a foreign body, which in turn
induces the state of chronic inflammation. Therefore, according
to our hypothesis, AD is associated with chronic hypoxia caused
by the gradual accumulation of parafibrin that is generated by
a non-enzymatic pathway and is totally resistant to the prote-
olytic degradation. By contrast, fibrin clots formed in the brain
by the action of thrombin, as in vascular dementia, are eventu-
ally removed by the powerful fibrinolytic enzyme system and may
not be found in “pure” AD. We suggest that parafibrin, which is
responsible for chronic brain hypoxia, is generated by the mech-
anisms other that the activation of blood coagulation. Therefore,
vascular risk factors are not detectable in patients with pure AD
(shown in Figure 1). In order to stop the vicious cycle it is neces-
sary to break this pathologic chain of events by: (1) limiting the
dietary supply of trivalent iron; (2) supplying sufficient quantities
of natural iron chelating substances (e.g., certain polyphenols); (3)
increasing the consumption of omega-3 fatty acids (e.g., fish oil)
and other unsaturated aliphatic and/or aromatic substances that
will scavenge hydroxyl radicals; and (4) increase the intake of Mg.
It should be noted that these conditions are already met in the so-
called Mediterranean diet, which is known to be associated with
lower incidence of cardiovascular and AD (Lourida et al., 2013).
Animal models of AD are frequently used to study the mechanisms
underlying AD pathogenesis, genetic interactions with genes of
interest, and environmental risk factors that cause sporadic AD,
as well as to test the therapeutic effects of AD drug-candidates
on neuropathology and cognitive function (Lee and Han, 2013).
An important next step with regard to this hypothesis would be
to investigate using, for example, animal models, the effect of Mg
and iron chelating, and/or hydroxyl radical scavengers.
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